Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Solymbic

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

- PMLiVE

AbbVie takes home company of the year at PMEA 2014

Firm is rewarded for its patient-focus

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

- PMLiVE

Amgen’s trebananib misses survival target in ovarian cancer

First phase III trial improved survival rates by just one month

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen appoints R Sanders Williams to board of directors

He is president of Gladstone Institutes

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links